The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited announced the FDA approval and upcoming market launch of Ryoncil® (remestemcel-L) at the Transplantation & Cellular Therapy Tandem Meetings. Ryoncil® is the first mesenchymal stromal cell therapy approved in the U.S. for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD) and is expected to enhance Mesoblast’s market position in cellular medicines. The product’s approval marks a significant milestone for the company, highlighting its leadership in the field and potential impact on patient care and industry standards.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines, focusing on treating severe inflammatory conditions. Utilizing proprietary mesenchymal lineage cell therapy technology, the company targets severe inflammation with anti-inflammatory factors. Mesoblast has a robust intellectual property portfolio and commercial partnerships in major markets like Japan, Europe, and China. The company is listed on the Australian Securities Exchange and Nasdaq.
YTD Price Performance: -26.36%
Average Trading Volume: 250,258
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $2.37B
See more insights into MSB stock on TipRanks’ Stock Analysis page.